Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Monday, July 22, 2024 | Back issues
Courthouse News Service Courthouse News Service


MANHATTAN - Sanofi issued contingent value rights at inflated prices when it acquired codefendant Genzyme, and the CVRs fell by 62 percent when misleading statements about the MS drug Lemtrada were revealed, investors claim in Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.